IQVIA reported solid third-quarter 2025 results, with revenues and profits at the high end of guidance, driven by robust operational performance and impressive free cash flow.

• Revenue growth of 5.2% year-over-year, with adjusted diluted EPS rising 5.6%.
• Record backlog of $32.4 billion, up 4.1% compared to the prior year, reflecting strong demand trends.
• Net bookings reached $2.6 billion, translating to a favorable net book-to-bill ratio of 1.15x, driven by improved customer demand.
• Continued strength in the TAS segment with successful drug launches contributing to overall results.
• Strong free cash flow this quarter marks the highest ever, highlighting effective working capital management.